International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

Vol. 43 No. 1 February 2024, pp. 370-379

Covid 2 Variants and Vaccines

Review

Maged Naser[1], and Lamia H. Shehata[2]

[1]Mazahmiya Hospital, Ministry of Health, Kingdom of Saudi Arabia, Department of ob/gyn,

[2]Care National Hospital, Department of Radiology

Abstract – Notwithstanding the rising natural and vaccines mediated immunity, a several nations have encountered a resurgence of the Covid disease of 2019 (Coronavirus) because of the development of severe acute respiratory syndrome Covid 2 (SARS-CoV-2) variations. From Alpha to Omicron, the variants of concern (VOC) have advanced several spike protein changes that might affect infection characteristics, like contagiousness and antigenicity. In this review, we depict the advancement of SARS-CoV-2, sum up current information on epidemiological and clinical highlights of the variants, and talk about the response techniques as far as vaccines to decrease the burden of Coronavirus.

Keywords – Coronavirus, SARS-CoV-2, Spike mutations, Variation of Concern, Vaccines

I. INTRODUCTION

Covid disease of 2019 (Coronavirus), an infection brought about by severe acute respiratory syndrome Covid 2 (SARS-CoV-2), was proclaimed a pandemic by the World Health Organization (WHO) on March 11, 2020 [1]. It has since spread worldwide and essentially affects general health and the economy. Accordingly, numerous nations have taken on many measures to forestall the development of the pandemic, for example, launching cross country inoculation campaigns and broad lock-down of civil activities. Nonetheless, after at first containing SARS-CoV-2, numerous nations are encountering a resurgence of Coronavirus because of the rise of new variants. These arising variants have sets of transformations that could affect infection attributes, for example, expanded transmission rate, disease seriousness, and chance of reinfection, in this way upgrading the level of hardships in decreasing the Coronavirus burden. In this review, we portray the advancement of SARS-CoV-2, sum up the key spike transformations revealed in various variants, and talk about the response methodologies for arising variants regarding vaccines.

1. Acute respiratory syndrome Covid 2 (SARS-CoV-2)

Toward the start of the pandemic (December 2019 to October 2020), SARS-CoV-2 extended universally with little proof of specific developmental strain. SARS-CoV-2 develops gradually with a rate of 1 × 10−3 substitutions/site/year (or around 2 substitutions for each genome each month) [2,3] because of the editing capability of an exonuclease protein encoded by non-structural gene nsp14 [4]. This rate is more slow than that of most RNA viruses. In any case, particular transformative pressure was obvious with the recognition of a viral variant containing spike change D614G. This specific variant was at first seen in early 2020; it then, at that point, spread worldwide, outcompeted previous viruses, and turned into the predominant structure with a prevalence of practically 100 % by June 2020 [5].Following the development of D614G replacement, several novel lineages with mutations happening essentially, however not only, in spike proteins have been accounted for. The majority of these transformations are convergent, meaning they happen freely in various lineages, potentially because of a reaction to the changing immune profile or chronic infections in people who are immunocompromised [6,7] or people getting partially effective

Corresponding Author: Maged Naser

interventions [8]. In December 2020, the B.1.1.7 variants, giving various genetic changes, arose in the Unified Realm (UK) [9]. Simultaneously, two different variations, B.1.351 and P.1 arose freely and caused a flood of new cases in South Africa [10] and Brazil [11], respectively. In January 2021, Manaus, Brazil, encountered a resurgence of Coronavirus because of the development of variation P.1 notwithstanding its high seroprevalence from the first epidemic wave [12]. Additionally, in April 2021, with the seroprevalence around 50% subsequent to getting through three floods of the SARS-CoV-2 pandemic, India experienced the fourth wave brought about by the B.1.617.2 variant [13]; this variant then, at that point, spread universally and dislodged different variants in numerous nations [14,15,16].

Toward the start of November 2021, a profoundly different variants B.1.1.529 with countless transformations was recognized in Botswana, South Africa [17]. From that point forward, South Africa has encountered a flood of cases, expanding from 280 to 800 cases each day; spreading quickly and displacing B.1.617.2., B.1.1.529 has turned into the prevailing variant in South Africa [18].SARS-CoV-2 variants that have extended broadly and shown the possibility to be related with expanded contagiousness, disease seriousness, or change in interactions with have resistance are named variant of concern (VOC) by the WHO. Variants that show comparable changes as VOC however spread less generally are named variant of interest (VOI). As of April 1, 2022, there are five VOCs grouped by WHO and are assigned as Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529). Albeit most transformations noticed are supposed to be either neutral or somewhat mild deleterious, the spike protein changes that might modify the antigenicity of the SARS-CoV-2 are of specific significance. Whether these transformations will modify the variants' pathogenicity, infectivity or antigenicity still needs to be entirely determined.

2. Spike protein

The ability of VOCs to get away from balance by antibodies evoked by infection, immunization, or therapeutic application has been generally contemplated [19, 20,21]. It is fundamental to know the structure and function of the spike protein to comprehend what changes in the SARS-CoV-2 spike protein mean for neutralization. The transmembrane spike glycoprotein is responsible for SARS-CoV-2 passage into the host cell. The spike protein is cleaved by furin into two subunits, S1 and S2. A part of the S1 subunit, named receptor-binding domain (RBD), can bind to the human angiotensin-converting enzyme 2 (ACE2) receptor and hence start the process involved with entering cells. A part of RBD called receptor-binding motif (RBM) forms direct contact with the ACE2 receptor. Spike RBD is likewise the primary target of neutralizing antibodies upon infection and is the way in to a vaccine or other therapeutic improvement [22]. Like RBD, the S1 amino-terminal domain (NTD) is additionally uncovered to the protein surface, and proof shows that NTD assumes a significant part in antigenicity too [23]. Most monoclonal antibodies (mAbs) bind to RBD, while others focus on the NTD. Moreover, some killing Abs may likewise tie to the S1 carboxy-domain or S2 subunit, yet RBD-targeting on and NTD-targeting on Abs might be significantly more potent [24].

A several changes in parts of the spike protein may fundamentally influence the neutralizing activity of mAbs, in this way empowering VOC and VOI to get away from immunity and spread in a populace with rising immunity. E484 is a significant residue on RBD that can be perceived by polyclonal antibodies in convalescent sera. It has been shown the way that amino acid substitution to K, Q or P can altogether decrease neutralization titers [25]. E484K, which is the substitution of amino acid glutamic acid (E) with lysine (K) at position 484 of RBD, is a getaway mutation that has been tracked down in the Beta and Gamma VOCs and some of the VOIs. It works with escape from antibodies in convalescent plasma [25, 26, 27] and several mAbs, for example, casirivimab and bamlanivimab [28,29]. Furthermore, E484K has additionally been displayed to escape from plasma samples gathered from individuals inoculated with mRNA antibodies [29]. Other RBD get away from changes incorporate K417 N/T and L452R. K417N/T is tracked down in the Beta, Gamma, and Omicron VOCs. They are related with escape from mAb, for example, etesevimab [30,31] yet stay susceptible to convalescent plasma and plasma from people inoculated with BNT162b2 or mRNA-1273 [32]. L452R is available in Delta, Omicron subvariants BA.4 and BA.5, and it has been displayed to decrease neutralizing activity by several mAbs [28,33] and convalescent plasma [33].

Several different transformations likewise add to the antigenicity of VOCs. For instance, N501Y is one more RBD mutation tracked down in the Alpha, Beta, Gamma, and Omicron VOCs. It has been displayed to increase ACE2 receptor affinity [30], yet its antigenic effect is restricted to a few of monoclonal Abs. Moreover, it is seldom associated with the decreased neutralizing activity of convalescent plasma or vaccine sera [32]. P681H/R is a transformation occurring near the S1/S2 furin cleavage site. It has been displayed to build SARS-CoV-2 virulance by expanding S1/S2 cleavage [34]. P681H is accounted for in Alpha and Omicron VOCs, while P681R is tracked down in the Delta VOC. One of the NTD changes, deletion at the position 69-70, has been demonstrated to be related with expanded viral replication [35]. It is likewise utilized as a proxy to screen specific VOCs

[36]. One widely involved PCR strategy for diagnosing SARS-CoV-2 enhances three target genes. At the point when one of the gene targets is missing (69/70 deletion), the spike gene target can't be intensified on a particular PCR assay, and this makes a reproducible peculiarity called S gene target failure (SGTF). SGTFs have been found in the Alpha and Omicron VOCs [18].

3. Alpha variation (B.1.1.7)

The Alpha VOC has various mutations in RBD, most outstandingly N501Y, P681H, and 69/70 deletion. SGTF has been utilized as a proxy to screen this variant. It originally arose in the UK in September 2020 and had been recognized in a several different nations, including the USA, by mid 2021 [37]. Informations recommend that the Alpha VOC is 43-90% a greater transmissibility than other prior lineages coursing in the UK [36,38,39]. Regarding infection severity, albeit some reports exhibited no obvious proof between the Alpha VOC and increase mortality [39,40], others have shown its relationship with additional severe disease [41,42,43].The Alpha variant is susceptible to most mAbs and covalescent and vaccine (mRNA-1273 and BNT162b2) sera [32,44,45]; be that as it may, its effect on antibody reaction in AZD1222 has been incosistent [46,47].

4. Beta variation (B.1.351)

The Beta VOC has three RBD transformations (N501Y, E484K, and K417N) and some NTD changes with the exception of 69/70 deletion. It was first recognized in South Africa in October 2020, and cases have been found outside South Africa from that point ever since. There is no obvious proof proposing a relationship of this variant with increased mortality, however some reports have shown that E484K change might influence neutralization by several mAbs, including casirivimab, bamlanivimab, and etesevimab [28,32,48]. Besides, the Beta variant is more resistent to neutralizing activity by convalescent plasma [48] and sera from people immunized with mRNA-1273, BNT162b2 [32], and AZD1222 [49].

5. Gamma variation (P.1)

RBD mutations N501Y, E484K, and K417N were recognized in the Gamma VOC. This variant caused a surge of infection in Manaus, where a larger part of the populace had proactively been infected with SARS-CoV-2, and it is related with expanded transmissibility, risks of reinfection, and mortality [11,12,50]. Like the Beta VOC, the Gamma variant is refractory to neutralizing the activity of several mAbs, convalescent plasma, and vaccine sera [48,51,52].

6. Delta variation (B.1.617.2)

The Delta VOC was first identified in India a while in early 2021. This variant contains RBD transformation L452R and furin cleavage site mutation P681. Furthermore, it has several other spike protein transformations (T19R, R158G, T478K, and D950N) and mutations inside orf3, orf7a, and nucleocapsid genes [53]. Quickly displacing the Alpha variant in various nations [14] and turning into the prevailing worldwide VOC, the Delta variant has shown expanded transmissibility as a result of the accompanying potential systems: higher infection viral load [54], longer span of shedding infectious virus [55], and a higher rate of reinfection because of antibody escape [56]. The susceptibility of the Delta VOC to convalescent plasma and sera from receipients of BNT162b2 and AZD1222 is decreased [47,56,57], however one review showed that BNT162b2 offered more protection from the Delta variant than AZD1222 did [58]. Likewise, the Delta VOC might be resistant to bamlanivimab and some other mAbs [47].

7. Omicron variation (B.1.1.529)

On November 26, 2021, Omicron was first recognized in Bostwana, South Africa. In the span of three weeks, new cases have additionally been distinguished in excess of 50 nations overall [59]. This variant was subsequently isolated into six subvariants to be specific BA.1, BA.2, BA.3, BA.4, BA.5, and BA.2.12.1, and they are genetically and antigenically not quite the same as one another [60]. Because of expanded transmissibility, BA.1 displaced Delta and become the around the world predominant SARS-CoV-2 strain [61]. BA.2 later replaced BA.1 quickly in several nations [59,62]. New Omicron subvariants keep on arising; BA.4/5 and BA.2.12.1 had turned into the predominant strain in South Africa and the US [63,64,65], and they generally present higher transmission advantage over BA.2 [66].Omicron contains in excess of 30 transformations in its spike proteins; a portion of these mutations, especially those including RBD and NTD, are anticipated to impact antibody neutralization epitopes. Omicron subvariants share several common transformations, yet they likewise have numerous special mutations of their own [67]. Shared transformations like E484, K417N, T478K, N501Y, and P681H are found in other VOCs, and they are reported for to be related with expanded transmissibility, higher ACE2 binding affinity, and higher antibody escape [59]. Notwithstanding these common

spike transformations, BA.1 conveys 13 more unique amino-acid mutations while BA.2 conveys 8 additional mutations [68]. BA.4, BA5, and BA.2.12.1 show same RBD arrangements to BA.2; moreover, BA.4 and BA5 contain L452R and F486V changes while BA.2.12.1 has L452Q substitutions [66].

Remarkably, like the Alpha variant, BA.1, BA.4, and BA.5 can be identified by SGTF due to 69/70 deletion, however BA.2 and BA.2.12.1 need 69/70 deletion. Several studies have shown diminished neutralizing activity of vaccine serum against Omicron BA.1. These vaccine incorporate two dosages of the ChAdOx1-S vaccine [69,70], two doses of the mRNA antibody (mRNA-1273 and BNT162b2 [69,70,71]), and heterologous vaccination with the ChAdOx1-S and BNT162b2 vaccines [69].Convalescent serum from people who had been infected with the Alpha, Beta or Delta VOC additionally showed low neutralizing activity against BA.1 [69,72]. Nonetheless, the serum samples gathered from people infected with SARS-CoV-2 and afterward vaccinated [69,72] and people vaccinated with boosters (third dose with mRNA vaccines) [61,70,71,72] showed noticeable neutralizing antibodies against BA.1. The neutralizing activities of vaccine serum against BA.1 and BA.2 are similar [68,73], and the vaccine effectiveness of booster doses against symptomatic infection and hospitalization is likewise similar for BA.1 and BA.2 [74]. Notwithstanding, one investigation discovered that comparing with BA.1, BA.2 was related with expanded susceptibility of infection for unvaccinated, completely vaccinated and booster vaccinated people [75]. BA.4/5 and BA.2.12.1, then again, display more neutralization evasion than BA.2 against the plasma from 3 doses of BNT162b2 [65] and CoronaVac [66].

Cross-reactivities between various VOCs and Omicron sub-variants have been explored. One review uncovered that unvaccinated people who had no past SARS-CoV-2 diseases before infection with BA.1 created neutralizing activity against BA.1 for the most part, and no significant activity against other VOCs was found [76]. Besides, albeit one review showed a specific level of cross-reactivity somewhere in the range of BA.1 and BA.2 [68], others tracked down poor cross-reactivity of BA.1/2-explicit neutralizing Abs against BA.4/5 and BA.2.12.1 [66,77].

Several remedial mAbs, including bamlanivimab, imdevimab, casirivimab, and etesevimab, were evaded by BA.1, BA.2, BA.4/5 and BA.2.12.1 [78]. Sotrovimab, in any case, had the option to keep up with its capability at a decreased efficacy against BA.2 when compared with Delta or D614G infection [64,[78], [79], [80]. In spite of the fact that sotrovimab was less successful against BA.2 than the parental virus, BA.4/5 BA.2.12.1 were more sensitive to sotrovimab than BA.2 [78]. Few other mAbs, for example, tixagevimab/cilgavimab and adintrevimab, were halfway dynamic against BA.2 and BA.4/5 [64,65,78,80].

6. Response to arising variants

Different SARS-CoV-2 variations have arisen freely all over the planet against the background of expanding populace immunity. Different strategies have been utilized to diminish the burden of VOCs and VOIs, and the greater part of the methodologies stay effective. For example, no report shows that current public health prevention measures, like wearing musk, social separating, and hand cleanliness, are ineffective against different variants. Additionally, several therapeutic mAbs (for example sotrovimab) and antiviral agents (for example remdesivir and molnupiravir) stay active against most VOCs and VOIs [21,81]. The protection given by the vaccines, nonetheless, might be the chief concern. Several nations are encountering the resurgence of Coronavirus due to arising VOCs and fading vaccine prompted immunity. Studies show a gradual winding down of immunity given by past dosages of Coronavirus vaccines [82,83], and some arising variants are less susceptible to neutralizing activity of these vaccines [84,85]. It is derived that in light of winding down immunity and the ascent of new variants, for example, Omicron, vaccine booster ought to be considered on the grounds that they can increment immunogenicity after the initial course of vaccines. Affinity maturation of antibodies might be the fundamental component of the improved humoral reaction against SARS-CoV-2 [86].

Besides, several studies have shown that administering a booster dose utilizing presently authorized mRNA vaccines can offer protection against symptomatic infection, hospitalization or mortality related with arising VOCs [74,87, 88,89]. Albeit a heterologous prime-boost schedule can be more immunogenic and reactogenic than a homologous prime-boost schedule [90,91], policymakers ought to in any case consider managing a booster dose to decrease severe Coronavirus related results. Presenting altered and new antibodies with antigens that are compelling against prior variants is one more conceivable answer for upgrade protection against emerging VOCs that might become vaccine resistent [92]. One review showed that utilizing a mRNA vaccine coordinated with spike mutations from the Beta variant as a booster can increment both wild-type and Beta variant neutralization titres in mice [93]. Nonetheless, more studies are expected to decide if new immunogens can evoke a more extensive and longer-enduring reaction to VOCs instead of boosting existing antibodies produced by past infections or current vaccinations. Up to that

point, genomic surveillance with kept sharing of information, public health prevention measures, and full vaccination with boosters might be the best systems to lighten the effect of emerging variants.

II. Conclusion

As we mentioned above, with Coronavirus spreading universally, SARS-CoV-2 goes through a serious level of genomic mutations that causes antigenic drift bringing about a break from immune recognition during the time spent adapting to the host. The variant "Deltacron", whose presence was affirmed by French scientists, has a possibly dramatic expansion in transmission because of its various mutation locales, raising far reaching public concerns (94). In the constantly creating circumstance where new variants are becoming dominating, individuals are going to positive and effective measures to manage this peculiarity. All nations assume an extraordinary part in vaccine innovative work, and there are different vaccines that have been recorded through clinical preliminaries. From the ongoing epidemic prevention circumstance, with the promotion of vaccination, the spread of SARS-CoV-2 will surely be controlled from now on. As of the finish of February 2022, multiple billion doses of Coronavirus vaccines had been administrated in China; with a vaccination rate of almost 90%, China has made great accomplishments in epidemic counteraction and control. We approach individuals all over the planet to be effectively inoculated, and antibodies ought to be similarly accessible to all regardless to race, colour, age, religion, wealth, and ethnicity.

The effectiveness of all ongoing vaccines against variants, particularly the Omicron variant, has been altogether decreased. Since the entire microorganism approach of involving a complete virus as a platform has a greater number of targets than the subunit approach or genetic methodology, we hypothesised that vaccines created with the whole organism approach will give more specific and effective protection than vaccines in light of the subunit approach or genetic methodology when new variants emerge. All vaccines presently infused have changing levels of side effects, including fever, migraine, weakness, muscle pain and joint pain, and, even, hypersensitive responses. Moreover, in some underdeveloped countries and districts, vaccination has not been advanced, and the preventive impact of antibody has not arrived at the expected goal. This shows that the innovation cycle of vaccine research work actually have space for advancement and improvement, including the utilization of new advances, for example, nanotechnology in the conveyance of antibodies and the control of harmful substances and temperature in the production cycle. On the future, researchers from various nations will actually want to plan vaccines against explicit variants with various mutation sites, utilizing more effective and scientific procedures to give sustained protection. By tending to these challenges, we firmly believe that Coronavirus will be defeated by mankind at last.

Conflict of Interest

All authors declare no conflicts of interest.

Author Contribution

Authors have equally participated and shared every item of the work.

References

[1]-Cucinotta, Domenico, and Maurizio Vanelli. "WHO declares COVID-19 a pandemic." *Acta bio medica: Atenei parmensis* 91.1 (2020): 157.

[2]-Candido, Darlan S., et al. "Evolution and epidemic spread of SARS-CoV-2 in Brazil."*Science* 369.6508 (2020): 1255-1260.

[3]-Pereson, Matías J., et al. "Phylogenetic analysis of SARS-CoV-2 in the first few months since its emergence." *Journal of medical virology* 93.3 (2021): 1722-1731.

[4]-Minskaia, Ekaterina, et al. "Discovery of an RNA virus 3′→ 5′ exoribonuclease that is critically involved in coronavirus RNA synthesis." *Proceedings of the National Academy of Sciences*103.13 (2006): 5108-5113.

[5]-Korber, Bette, et al. "Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus." *Cell* 182.4 (2020): 812-827.

[6]-Choi, Bina, et al. "Persistence and evolution of SARS-CoV-2 in an immunocompromised host." *New England Journal of Medicine* 383.23 (2020): 2291-2293.

[7]-Avanzato, Victoria A., et al. "Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer." *Cell* 183.7 (2020): 1901-1912.

[8]-Kemp, Steven A., et al. "SARS-CoV-2 evolution during treatment of chronic infection." *Nature* 592.7853 (2021): 277-282.

[9]-Rambaut, Andrew, et al. "Preliminary genomic characterisation of an emergent SARSCoV-2 lineage in the UK defined by a novel set of spike mutations. COVID-19 Genomics Consortium UK (CoG-UK)." (2020).

[10]-Tegally, Houriiyah, et al. "Detection of a SARS-CoV-2 variant of concern in South Africa." *Nature* 592.7854 (2021): 438-443.

[11]-Faria, Nuno R., et al. "Genomics and epidemiology of the P. 1 SARS-CoV-2 lineage in Manaus, Brazil." *Science* 372.6544 (2021): 815-821.

[12]-Sabino, Ester C., et al. "Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence." *The Lancet* 397.10273 (2021): 452-455.

[13]-Dhar, Mahesh S., et al. "Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India."*Science* 374.6570 (2021): 995-999.

[14]-Riley, Steven, et al. "REACT-1 round 12 report: resurgence of SARS-CoV-2 infections in England associated with increased frequency of the Delta variant."MedRxiv(2021): 2021-06.

[15]-Tegally, Houriiyah, et al. "Rapid replacement of the Beta variant by the Delta variant in South Africa."MedRxiv(2021): 2021-09.

[16]-Bolze, Alexandre, et al. "SARS-CoV-2 variant Delta rapidly displaced variant Alpha in the United States and led to higher viral loads." *Cell Reports Medicine*3.3 (2022).

[17]-WHO, Tracking SARS. "CoV-2 variants."World Health Organization(2021).

[18]-Walensky, Rochelle P., Henry T. Walke, and Anthony S. Fauci. "SARS-CoV-2 variants of concern in the United States—challenges and opportunities."Jama325.11 (2021): 1037-1038.

[19]-Harvey, William T., et al. "SARS-CoV-2 variants, spike mutations and immune escape."*Nature reviews microbiology*19.7 (2021): 409-424.

[20]-Lazarevic, Ivana, et al. "Immune evasion of SARS-CoV-2 emerging variants: what have we learnt so far?."*Viruses*13.7 (2021): 1192.

[21]-Tao, Kaiming, et al. "The biological and clinical significance of emerging SARS-CoV-2 variants."*Nature Reviews Genetics*22.12 (2021): 757-773.

[22]-Piccoli, Luca, et al. "Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology."*Cell*183.4 (2020): 1024-1042.

[23]-Suryadevara, Naveenchandra, et al. "Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein."*Cell*184.9 (2021): 2316-2331.

[24]-Poh, Chek Meng, et al. "Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients."*Nature communications*11.1 (2020): 2806.

[25]-Greaney, Allison J., et al. "Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies."*Cell host & microbe*29.3 (2021): 463-476.

[26]-McCarthy, Kevin R., et al. "Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape."*Science*371.6534 (2021): 1139-1142.

[27]-Weisblum, Yiska, et al. "Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants."*elife*9 (2020): e61312.

[28]-Liu, Zhuoming, et al. "Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization."*Cell host & microbe*29.3 (2021): 477-488.

[29]-Baum, Alina, et al. "Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies."*Science*369.6506 (2020): 1014-1018.

[30]-Starr, Tyler N., et al. "Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding."*cell*182.5 (2020): 1295-1310.

[31]-Starr, Tyler N., et al. "Prospective mapping of viral mutations that escape antibodies used to treat COVID-19."*Science*371.6531 (2021): 850-854.

[32]-Wang, Pengfei, et al. "Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7."*Nature*593.7857 (2021): 130-135.

[33]-Li, Qianqian, et al. "The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity."*Cell*182.5 (2020): 1284-1294.

[34]-Johnson, Bryan A., et al. "Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis."*Nature*591.7849 (2021): 293-299.

[35]-Meng, Bo, et al. "Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B. 1.1. 7."*Cell reports*35.13 (2021).

[36]-Volz, Erik, et al. "Assessing transmissibility of SARS-CoV-2 lineage B. 1.1. 7 in England."*Nature* 593.7858 (2021): 266-269.

[37]-for Immunization, National Center. "Science Brief: SARS-CoV-2 and Surface (Fomite) Transmission for Indoor Community Environments."CDC COVID-19 Science Briefs [Internet]. Centers for Disease Control and Prevention (US), 2021.

[38]-Lyngse, Frederik Plesner, et al. "Increased transmissibility of SARS-CoV-2 lineage B. 1.1. 7 by age and viral load."*Nature Communications*12.1 (2021): 7251.

[39]-Davies, Nicholas G., et al. "Estimated transmissibility and impact of SARS-CoV-2 lineage B. 1.1. 7 in England."*Science*372.6538 (2021): eabg3055.

[40]-Frampton, Dan, et al. "Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B. 1.1. 7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study."*The Lancet infectious diseases*21.9 (2021): 1246-1256.

[41]-Davies, Nicholas G., et al. "Increased mortality in community-tested cases of SARS-CoV-2 lineage B. 1.1. 7."*Nature*593.7858 (2021): 270-274.

[42]-Challen, Robert, et al. "Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study."*bmj*372 (2021).

[43]-Giles, Benjamin, et al. "The SARS-CoV-2 B. 1.1. 7 variant and increased clinical severity—the jury is out."*The Lancet Infectious Diseases*21.9 (2021): 1213-1214.

[44]-Chen, Xinhua, et al. "Neutralizing Antibodies Against SARS-CoV-2 Variants Induced by Natural Infection or Vaccination: A Systematic Review and Individual Data Meta-Analysis." (2021).

[45]-Collier, Dami A., et al. "Sensitivity of SARS-CoV-2 B. 1.1. 7 to mRNA vaccine-elicited antibodies."*Nature*593.7857 (2021): 136-141.

[46]-Emary, Katherine RW, et al. "Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial."*The Lancet*397.10282 (2021): 1351-1362.

[47]-Planas, Delphine, et al. "Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization."*Nature*596.7871 (2021): 276-280.

[48]-Chen, Rita E., et al. "Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies."*Nature medicine*27.4 (2021): 717-726.

[49]-Madhi, Shabir A., et al. "Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant."*New England Journal of Medicine*384.20 (2021): 1885-1898.

[50]-Freitas, André Ricardo Ribas, et al. "The increase in the risk of severity and fatality rate of covid-19 in southern Brazil after the emergence of the Variant of Concern (VOC) SARS-CoV-2 P. 1 was greater among young adults without pre-existing risk conditions."MedRxiv(2021): 2021-04.

[51]-Wang, Pengfei, et al. "Increased resistance of SARS-CoV-2 variant P. 1 to antibody neutralization."*Cell host & microbe*29.5 (2021): 747-751.

[52]-Dejnirattisai, Wanwisa, et al. "Antibody evasion by the P. 1 strain of SARS-CoV-2."*Cell*184.11 (2021): 2939-2954.

[53]-Chen, Kai-Wei K., Daniel Tsung-Ning Huang, and Li-Min Huang. "SARS-CoV-2 variants–evolution, spike protein, and vaccines."*biomedical journal*45.4 (2022): 573-579.

[54]-Luo, Chun Huai, et al. "Infection with the SARS-CoV-2 delta variant is associated with higher infectious virus loads compared to the alpha variant in both unvaccinated and vaccinated individuals."MedRxiv(2021).

[55]-van Kampen, Jeroen JA, et al. "Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)."*Nature communications* 12.1 (2021): 267.

[56]-Liu, Chang, et al. "Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine and convalescent serum."*Cell*184.16 (2021): 4220-4236.

[57]-Wall, Emma C., et al. "Neutralising antibody activity against SARS-CoV-2 VOCs B. 1.617. 2 and B. 1.351 by BNT162b2 vaccination."*The Lancet*397.10292 (2021): 2331-2333.

[58]-Sheikh, Aziz, et al. "SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness."*The Lancet* 397.10293 (2021): 2461-2462.

[59]-Jacob, Jobin John, et al. "Evolutionary tracking of SARS-CoV-2 genetic variants highlights an intricate balance of stabilizing and destabilizing mutations."MBio12.4 (2021): 10-1128.

[60]-Mykytyn, Anna Z., et al. "Omicron BA. 1 and BA. 2 are antigenically distinct SARS-CoV-2 variants."BioRxiv(2022): 2022-02.

[61]-Garcia-Beltran, Wilfredo F., et al. "mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant."*Cell*185.3 (2022): 457-466.

[62]-Chen, Jiahui, and Guo-Wei Wei. "Omicron BA. 2 (B. 1.1. 529.2): high potential for becoming the next dominant variant."*The journal of physical chemistry letters*13.17 (2022): 3840-3849.

[63]-Tegally, Houriiyah, et al. "Continued emergence and evolution of Omicron in South Africa: New BA. 4 and BA. 5 lineages."MedRxiv(2022): 2022-05.

[64]-Cao, Yunlong, et al. "Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies."*Nature*602.7898 (2022): 657-663.

[65]-Hachmann, Nicole P., et al. "Neutralization escape by SARS-CoV-2 Omicron subvariants BA. 2.12. 1, BA. 4, and BA. 5."*New England Journal of Medicine*387.1 (2022): 86-88.

[66]-Cao, Yunlong, et al. "BA. 2.12. 1, BA. 4 and BA. 5 escape antibodies elicited by Omicron infection."Nature608.7923 (2022): 593-602.

[67]-Viana, Raquel, et al. "Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa."*Nature*603.7902 (2022): 679-686.

[68]-Yu, Jingyou, et al. "Neutralization of the SARS-CoV-2 Omicron BA. 1 and BA. 2 variants."*New England Journal of Medicine*386.16 (2022): 1579-1580.

[69]-Rössler, Annika, et al. "SARS-CoV-2 Omicron variant neutralization in serum from vaccinated and convalescent persons."*New England Journal of Medicine*386.7 (2022): 698-700.

[70]-Planas, Delphine, et al. "Considerable escape of SARS-CoV-2 Omicron to antibody neutralization."*Nature*602.7898 (2022): 671-675.

[71]-Carreño, Juan Manuel, et al. "Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron."*Nature*602.7898 (2022): 682-688.

[72]-Schmidt, Fabian, et al. "Plasma neutralization of the SARS-CoV-2 Omicron variant." *New England Journal of Medicine*386.6 (2022): 599-601.

[73]-Bowen, John E., et al. "Omicron BA. 1 and BA. 2 neutralizing activity elicited by a comprehensive panel of human vaccines."BioRxiv(2022).

[74]-Halford, Florence, et al. "Temporal changes to adult case fatality risk of COVID-19 after vaccination in England between May 2020 and February 2022: a national surveillance study."Journal of the Royal Society of Medicine(2023): 01410768231216332.

[75]-Lyngse, Frederik Plesner, et al. "Transmission of SARS-CoV-2 Omicron VOC subvariants BA. 1 and BA. 2: evidence from Danish households."MedRxiv(2022): 2022-01.

[76]-Rössler, Annika, et al. "Neutralization profile after recovery from SARS-CoV-2 omicron infection."New England Journal of Medicine386.18 (2022): 1764-1766.

[77]-Khan, Khadija, et al. "Omicron sub-lineages BA. 4/BA. 5 escape BA. 1 infection elicited neutralizing immunity."MedRXiv(2022): 2022-04.

[78]-Yamasoba, Daichi, et al. "Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies."The Lancet Infectious Diseases22.7 (2022): 942-943.

[79]-Sheward, Daniel J., et al. "Neutralisation sensitivity of the SARS-CoV-2 omicron (B. 1.1. 529) variant: a cross-sectional study."The Lancet Infectious Diseases22.6 (2022): 813-820.

[80]-Cameroni, Elisabetta, et al. "Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift."Nature602.7898 (2022): 664-670.

[81]-Cathcart, Andrea L., et al. "The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2."biorxiv(2021): 2021-03.

[82]-Goldberg, Yair, et al. "Waning immunity after the BNT162b2 vaccine in Israel."New England Journal of Medicine385.24 (2021): e85.

[83]-Khoury, David S., et al. "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection."Nature medicine27.7 (2021): 1205-1211.

[84]-Chemaitelly, Hiam, et al. "Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar."New England Journal of Medicine385.24 (2021): e83.

[85]-Pouwels, Koen B., et al. "Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK."Nature medicine27.12 (2021): 2127-2135.

[86]-Wang, Zijun, et al. "Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection."Nature595.7867 (2021): 426-431.

[87]-Arbel, Ronen, et al. "BNT162b2 vaccine booster and mortality due to Covid-19." New England Journal of Medicine385.26 (2021): 2413-2420.

[88]-Bar-On, Yinon M., et al. "Protection against Covid-19 by BNT162b2 booster across age groups."New England Journal of Medicine385.26 (2021): 2421-2430.

[89]-Munro, Alasdair PS, et al. "Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial."The Lancet398.10318 (2021): 2258-2276.

[90]-Liu, Xinxue, et al. "Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial."The Lancet398.10303 (2021): 856-869.

[91]-Shaw, Robert H., et al. "Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data."The Lancet397.10289 (2021): 2043-2046.

[92]-Krause, Philip R., et al. "SARS-CoV-2 variants and vaccines."New England Journal of Medicine385.2 (2021): 179-186.

[93]-Wu, Kai, et al. "Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice."Vaccine39.51 (2021): 7394-7400.

[94]-Colson, Philippe, et al. "Culture and identification of a “Deltamicron” SARS-CoV-2 in a three cases cluster in southern France."Journal of Medical Virology94.8 (2022): 3739-3749.